Ghana’s Health System and Donor Funding: The Reality, the Gains and the Growing Risk

For decades, international development partners have played an important role in financing Ghana’s health sector, supporting programmes ranging from HIV/AIDS and tuberculosis treatment to malaria control, immunisation, maternal health and disease surveillance.

The support has saved lives, strengthened health facilities and made essential medicines and vaccines available to millions of Ghanaians. But as international aid priorities change and Ghana seeks to consolidate its middle-income status, an important question has become increasingly urgent: Can the country sustain essential health services if donor funding declines?

Ghana's health system is financed principally through government budgetary allocations, the National Health Insurance Scheme (NHIS), household out-of-pocket expenditure and support from development partners.

Although donor funding does not finance most healthcare expenditure across the entire system, some critical public-health programmes remain heavily dependent on external assistance.

Programmes targeting HIV/AIDS, tuberculosis, malaria, immunisation, family planning and maternal and child health have historically received substantial support from organisations and initiatives including the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, the Vaccine Alliance, the World Health Organization, the World Bank and bilateral development partners.

This means that medicines, diagnostic equipment, vaccines, mosquito nets, laboratory services, disease-surveillance systems and health-worker training available to Ghanaian patients may, directly or indirectly, have benefited from international financing.

Donor Support Has Saved Lives
The contribution of development partners to Ghana's health achievements cannot be underestimated.

International assistance has helped expand access to antiretroviral therapy for people living with HIV, strengthened tuberculosis diagnosis and treatment, financed malaria prevention programmes and supported the procurement and distribution of insecticide-treated mosquito nets.

External support has also contributed significantly to childhood immunisation, laboratory capacity, disease surveillance, reproductive health programmes and emergency responses to outbreaks.

These interventions have helped Ghana make considerable progress in controlling communicable diseases and improving maternal and child health.

But what has been an important source of strength could become a vulnerability if the country fails to prepare adequately for declining external assistance.

The Sustainability Challenge
The international development financing environment is changing. Donor governments face competing domestic and global priorities, while international health organisations are increasingly demanding greater domestic co-financing from beneficiary countries.

Ghana's economic development also means that, over time, the country may become less eligible for some forms of concessional assistance.

This creates what health financing experts often describe as a transition challenge: donor assistance may decline faster than domestic resources increase.

If that happens without careful planning, the consequences could include shortages of essential medicines and diagnostic supplies, interruptions in treatment programmes and greater financial pressure on patients and health facilities.

The challenge is particularly serious for diseases requiring uninterrupted treatment. A person receiving antiretroviral medicines or tuberculosis treatment cannot simply wait several months because procurement funding has been delayed.

Ghana therefore needs to regard health financing not merely as an annual budgetary issue but as a matter of national security and long-term development.

NHIS Must Be Strengthened
The National Health Insurance Scheme remains one of Ghana's most important mechanisms for achieving universal health coverage.

However, concerns about delayed reimbursements to healthcare providers, increasing treatment costs and the financial sustainability of the scheme have persisted.

When health facilities are not reimbursed promptly, their ability to purchase medicines, maintain equipment and provide quality services can be affected.

Strengthening the NHIS must therefore form an essential part of any strategy to reduce Ghana's dependence on development assistance.

Government must also explore sustainable domestic financing mechanisms that can provide predictable funding for essential medicines, vaccines and public-health programmes.

Local Pharmaceutical Production Is Critical

Another important part of the solution is domestic manufacturing.

Ghana cannot achieve genuine health security while remaining excessively dependent on imported medicines, vaccines, diagnostic products and other essential medical supplies.

Supporting Ghanaian pharmaceutical manufacturers could reduce some import dependence, create skilled employment, strengthen supply chains and retain more healthcare expenditure within the domestic economy.

Government procurement policies can also be structured to encourage competitive local production without compromising quality and patient safety.

The lessons from recent global health emergencies are clear: countries without resilient domestic supply chains can quickly find themselves competing internationally for essential medical products.

Prevention Must Become a Financing Strategy

Ghana must equally invest more aggressively in disease prevention.

Preventing malaria, hypertension, diabetes, hepatitis, HIV infection and other illnesses is generally less costly than managing advanced disease and its complications.

Improved sanitation, vaccination, health education, screening, nutrition and early diagnosis should therefore be regarded not simply as health interventions but as long-term economic investments.

Every preventable hospital admission places additional pressure on the NHIS, government expenditure, families and already stretched health facilities.

Ghana Needs a Clear Transition Plan
The country should develop a comprehensive national strategy for gradually assuming responsibility for programmes currently supported substantially by development partners.

Such a strategy should include increased and predictable domestic health financing, stronger NHIS funding and accountability, timely reimbursement of healthcare providers, greater investment in prevention and expanded local production of essential medicines and medical supplies.

Donor-supported programmes should also be progressively integrated into Ghana's national health structures so that essential services do not collapse when individual projects or grants come to an end.

Development partners have made an enormous contribution to Ghana's health sector, and international cooperation will continue to be important. The objective should not be to reject donor assistance but to ensure that Ghana's essential health services can survive without depending indefinitely on it.

The warning signs are clear.
If external health financing declines substantially before domestic financing is ready to replace it, patients will ultimately bear the consequences.

After decades of international assistance, Ghana must now accelerate the transition from donor-supported healthcare to sustainably financed national healthcare.

The future of the country's health system should not depend on whether another country, foundation or international organisation decides to renew a grant.

Donor support can help build the system, but ultimately Ghana must be capable of financing the essential healthcare of its own people.